FINWIRES · TerminalLIVE
FINWIRES

受需求疲軟影響,Avista第一季各業務板塊能源銷售量均下滑

By

-- Avista (AVA) 週二公佈了第一季財報。受溫和天氣影響,電力和天然氣需求下降,其中居民用電量下降 10%,商業用電量下降 6%。 該公司報告稱,其營運部門 Avista Utilities 的居民用電總量為 1.15 吉瓦時,低於去年同期的 1.27 吉瓦時。 截至 3 月 31 日的第一季度,商業用電量為 768 兆瓦時,低於去年同期的 808 兆瓦時。 該公司報告稱,第一季工業用電量為 455 兆瓦時,低於去年同期的 469 兆瓦時;批發用電量為 912 兆瓦時,低於去年同期的 951 兆瓦時。 該公司報告稱,其營運部門 Avista Utilities 的住宅天然氣總銷量為 8,4907 億英熱單位(Btu),低於去年同期的 9,8,881 億英熱單位。 截至 3 月 31 日的季度,商業天然氣銷售量為 5,1161 億英熱單位,低於去年同期的 5,9619 億英熱單位。 該公司報告稱,第一季天然氣批發量為 5,4,461 億英熱單位,低於去年同期的 6,7,528 億英熱單位。 其他天然氣銷售量為 5,4461 億英熱單位,低於去年同期的 5,4019 億英熱單位。 Avista 也正在推動一項新的企業資源規劃系統,該系統計劃於 2028 年完成,預計資本支出約為 1.3 億美元,旨在提高營運效率和財務報告能力。

Price: $40.81, Change: $+0.25, Percent Change: +0.62%

Related Articles

Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Posco Holdings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to USD94 from USD70, valuing POSCO at 0.66x 2026 P/BV, above its three-year mean of 0.52x. Our neutral view reflects: (i) recovering steel fundamentals supported by China's 2025 crude steel output declining 4.4% Y/Y and South Korea's anti-dumping duties on Chinese steel, which provides a pricing moat for Posco; and (ii) lithium market recovery with prices surging 49% YTD through April, supporting POSCO's battery materials segment which narrowed Q1 2026 losses significantly. POSCO's Australian and Argentine lithium acquisitions bolster its battery materials growth strategy. Additionally, the new Mid-term Shareholder Return Policy (2026-2028) targeting a 35%-40% payout ratio demonstrates commitment to shareholder value. However, risks include an aggressive 61% capex increase to KRW11.3 trillion in 2026, execution challenges on international projects, and persistent margin pressures. We adjust our 2026 EPS estimate to KRW6,379 from KRW5,932 and 2027 to KRW8,036 from KRW7,820.

$PKX
Research

Propel Holdings Maintained at Buy at Stifel Canada After Q1 Results; Price Target Kept at C$32.00

Stifel Canada on Tuesday reiterated its buy rating on the shares of Propel Holdings (PRL.TO) and its C$32.00 price target following the company's first-quarter results."Propel reported an upside FQ1, underscoring strength in loan growth alongside stable credit performance, on the back of the rebound in credit quality and subsequent new origination activity we saw exiting last quarter. Importantly, credit metrics PCLs and net-charge-offs normalized this quarter, supporting a recovery in ROE and fueling yet another bump in Propel's quarterly dividend (11th consecutive raise at +6.7% to $0.24/share). Net/net - results further reinforce resilience in the non-prime consumer backdrop, in-line with recent prints from US consumer credit peers. FY guide is being maintained, reaffirming the growth trajectory ahead, while suggesting some conservatism amidst the current macro uncertainty. Conference call tomorrow at 8:30am ET (dial-in: 1-888-699-1199/webcast). Our key focus on the call will be around (1) outlook for US consumer credit quality, (2) growth outlook for LaaS, (3) pace/scale of ongoing growth investments to support US expansion/Propel Bank launch," analyst Suthan Sukumar wrote.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $24.15, Change: $+2.25, Percent Change: +10.27%

$PRL.TO
Australia

Correction: BioNTech Q1 Adjusted Loss Widens, Revenue Declines; Reaffirms 2026 Revenue Outlook

(Corrects the year-ago revenue to 182.8 million euros in the third paragraph.)BioNTech (BNTX) reported a Q1 adjusted loss Tuesday of 1.95 euros ($2.28) per diluted share, widening from a loss of 1.79 euros a year earlier.Analysts polled by FactSet expected a loss of 1.27 euros.Revenue for the quarter ended March 31 was 118.1 million euros, compared with 182.8 million euros a year earlier.Analysts surveyed by FactSet expected 164.6 million euros.For 2026, the company reaffirmed revenue of between 2 billion euros and 2.30 billion euros. Analysts polled by FactSet expect 2.22 billion euros.BioNTech shares were down nearly 4.4% in Tuesday premarket activity.Price: $96.56, Change: $-2.79, Percent Change: -2.81%

$BNTX